Infinita City
Stranded Technologies Podcast
Infinita is building a network city for longevity biotech acceleration, starting with a first physical hub in Prospera ZEDE, in Roatan (Honduras). This is the Infinita community's main channel for news, podcast episodes, event announcements & more. www.infinitacitytimes.com
No dejes de visitar la web del podcast y apoyar a su creador: www.infinitacitytimes.com
Autor
Infinita City
Categoría
Web del podcast
Último episodio
12 de nov. de 2026
¿Dónde escuchar?
Podcasts en la app Replaio Radio Muy prontoLos podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts
Episodios
Ep. 120: Ian Huyett and Andrew Ittleman on How the FDA Got Its Power Over Medicine 12.11.2026 1:08:33
In this episode, Niklas sits down with attorneys Ian Huyett, who works on litigation and state-level health reform, and Andrew Ittleman, who represents FDA-regulated companies and litigated Regenerative Sciences v. FDA, to talk about where the FDA’s authority comes from and how it applies when a doctor treats a patient inside one state. The conversation goes on to cover the 1938 law behind that au...
Ep. 119: Jess Flanigan on Why Patients Should Be Able to Choose Their Own Medicine 22.10.2026 59:18
Jess Flanigan is a philosopher at the University of Richmond, where she holds the Richard L. Morrill Chair in Ethics and Democratic Values. She is the author of Pharmaceutical Freedom, which argues that patients should have the right to choose their own medicines, not just refuse them. Her work covers human challenge trials, seatbelt mandates, billionaires, and charismatic leadership, and she has...
Ep. 118: Holly Fernandez on the Ethics and Practice of Pre-Approval Drug Access through Expanded Access vs. Right-to-Try 08.10.2026 1:19:31
Holly Fernandez Lynch is is Associate Professor of Medical Ethics and Law at the University of Pennsylvania, and one of the most influential voices in US bioethics on questions of clinical trial ethics, patient access, and research participant compensation. Holly was an opponent of the 2017 federal right-to-try act, joined Niklas to debate the problems with right-to-try vs. expanded access, and th...
Ep. 117: John Cochrane on Rethinking Healthcare, Markets, Regulation & the FDA 24.09.2026 1:02:23
John Cochrane, economist and professor of finance at Stanford Graduate School of Business and fellow at the Hoover Institution, joins the podcast to discuss the first principles of healthcare regulation. John debunks three arguments most commonly used to justify heavy healthcare regulation: that the poor need protection, that patients lack the information to choose well, and that people in a healt...
Ep. 116: Anthony DiGiorgio & Anish Koka on the Rules That Undermine Independent Medicine and Misaligned Healthcare Incentives from Practitioners’ Perspectives 10.09.2026 1:05:14
Niklas sits down with Dr. Anish Koka, a practicing cardiologist, and Dr. Anthony DiGiorgio, a neurosurgeon and academic, co-hosts of The Doctor’s Lounge. It’s a dense conversation about why the US healthcare system is structurally built to favor consolidation, bureaucracy, and large hospital systems, rather than independent doctors or patients. They break down specific rules working against indepe...
Ep. 115: Crémieux & Soham Sankaran -The Case for Vaccine Acceleration (vacc/acc) 27.08.2026 1:03:54
Soham is the founder of PopVax, a company building vaccines faster and cheaper using AI, mRNA platforms, and a radically efficient preclinical pipeline based in India. Crémieux is a pseudonymous writer and researcher known for data-driven essays on genetics, drug regulation, and biotech policy. In this episode, we break down how vaccines actually work, why they may be one of the most powerful long...
Ep. 114: The Ultimate Guide to Montana SB535: A US State’s Path to Accelerate Biotech & Patient Access 14.08.2026 1:26:52
In this episode, Niklas Anzinger sits down with Stephen Martin, U.S. Lead at Infinita and Operations Lead of the Montana Experimental Treatment Review Board (ETRB), to explore what could become a new model for biotech development and patient access in the United States. Montana SB 535, is a new framework allowing eligible post-Phase 1 experimental treatments to reach patients under regulated overs...
Ep. 113. Reason on Clinical Trials, Medical Tourism, and the Data the FDA Won’t See 30.07.2026 53:39
Reason, co-founder and CEO of Repair Biotechnologies and a longevity industry veteran with a background in astrophysics, joins us to talk about what it actually takes to test a therapy on humans, and why the system built to protect patients often keeps the best evidence hidden. He breaks down why investors backing gene and cell therapies care more about a drug’s earning potential than whether it w...
Ep. 112: Tim Urban on Startup Cities, AI Safety, Longevity, and Building Better Societies 16.07.2026 57:39
Tim Urban, creator of Wait But Why and the mind behind one of the most-watched TED Talks of all time, joins us to talk about why progress does not happen automatically. In this episode, he discusses the Space Race, longevity, AI safety, startup cities, and the social conditions that allow new ideas to survive. Tim explains why some technologies move fast while others stall for decades, why the bes...
Ep. 110: Tomas Pueyo & Trey Goff On The Next Silicon Valley Might Be A New Country 04.06.2026 2:27:21
In this episode, the famous blogger Tomas Pueyo (Uncharted Territories) interviews Trey Goff (Chief of Staff & Head of Public Policy at Prospera) & Niklas Anzinger (Founder & CEO of Infinita City). The interview is part of the research that Tomas did for a deep piece on “ The Cold Start Problem of New Cities ”, as Niklas & Trey are two of the most experienced practitioners in this emerging industr...
Ep. 109: Jonathan Anomaly on The Future of Human Enhancement, Genetic Selection & Startup Societies 21.05.2026 1:21:40
In this episode, Jonathan Anomaly joins us to discuss the collapse of trust in modern institutions, the rise of tribal politics, and why liberty increasingly depends on exit rather than persuasion. We explore embryo selection, genetics, rational irrationality, startup societies, academia, media manipulation, and the future of liberalism in an age of polarization. From controversial ideas to practi...
Ep. 108: The Buck Inst. President, Eric Verdin, on Pathways to Life Extension Acceleration: Alternative Pathways and Radical Hopium vs. Scientific Realism 08.05.2026 46:04
In this episode, we sit down with Eric Verdin, CEO of the Buck Institute, one of the world’s leading institutes dedicated to aging and longevity research. Eric has often been associated with a more rigorous and incremental approach to extending human lifespan, focused on scientific validation, measurable progress, and improving healthspan before chasing more radical ambitions. In contrast, the bro...
Ep. 107: Sid Sijbrandij On Beating Cancer with First Principles, n = 1 Personalized Treatments and Special Access Regulatory Pathways 10.04.2026 47:22
Sid Sijbrandij is the co-founder of GitLab, one of the world’s largest open-source software companies. But in 2022, his life took a radical turn — he was diagnosed with a rare and aggressive form of cancer. Instead of relying solely on the medical system, Sid took a different approach. He ran every diagnostic imaginable, developed experimental treatments, combined therapies, and ultimately built h...
Ep. 106: Yaron Brook: Capitalism, Ayn Rand, and the Moral Case for Freedom 18.03.2026 1:12:53
Yaron Brook, chairman of the Ayn Rand Institute and host of the Yaron Brook Show, joins Niklas to discuss the moral and philosophical foundations of capitalism. They explore Ayn Rand’s philosophy of Objectivism, the ethical case for individual freedom, and why capitalism is often misunderstood in modern political discourse. The conversation also touches on libertarian governance, free private citi...
Ep. 105: Andrew Hessel: Programming DNA and Engineering the Future of Life 20.02.2026 1:05:42
In this episode, he and Niklas explore how genome sequencing, DNA synthesis, and CRISPR are turning life into an engineering platform. From coding proteins and viruses to writing entire genomes, Andrew explains how biotech is moving from reading DNA to actively programming it. They discuss N-of-1 personalized therapies, biosecurity in an age of cheap DNA synthesis, and why open science could accel...
Ep. 104: Ruxandra Teslo: Clinical Trials, Drug Innovation, and the Bottleneck to Biotech Abundance 20.02.2026 1:02:38
In this episode, she and Niklas explore why drug development takes over a decade, why only ~10% of drugs reach approval, and how clinical trials have become one of the biggest bottlenecks to biomedical progress. They unpack how incentives distort which diseases get treated, why surrogate endpoints matter, and how off-label use, real-world data, and even “bro science” reveal gaps in the current sys...
Ep. 103: Ian Huyett on Right to Try, Christian Techno Optimism, and Biotech Federalism 17.12.2025 1:03:20
Ian Huyett is an attorney at Cornerstone in New Hampshire, where he leads litigation and policy work for a network of over one hundred churches. He helped design New Hampshire’s new Right to Try framework, which provides some of the strongest protections in the U.S. for patients seeking access to experimental treatments. Read the Essay: The Christian War on Death How Christianity reframed mortalit...
Ep. 111: Antonio García Martínez on Crypto, Network States, and Building New Cities 12.12.2025 49:21
Antonio Garcia Martinez is a writer, entrepreneur, and director at Base, Coinbase’s Ethereum L2. Before that he sold a startup to Twitter, worked on ads at Facebook, and wrote Chaos Monkeys , his memoir about the early ad-tech world. This session was recorded live in the Infinity Dome in Prospera. Antonio explains why crypto is not just a new financial system. It is a direct challenge to one of th...
Ep. 102: Arjun Khemani: Zcash, Radical Privacy, and the New Renaissance 28.11.2025 57:46
Arjun Khemani is one of the sharpest young thinkers in the progress movement. He dropped out of high school at 16, built apps with Naval’s team, ran a podcast with guests like David Deutsch and Balaji, and found himself inside the Bitcoin–Zcash privacy debate before turning 20. Niklas sits down with Arjun to explore how COVID shifted his worldview, how The Beginning of Infinity pushed him toward a...
Ep. 101: Bryan Caplan: Pro Market & Pro Business, the Real Ethics of Entrepreneurship 14.11.2025 1:05:41
Ep. 101: Bryan Caplan: Pro Market & Pro Business, the Real Ethics of Entrepreneurship Bryan Caplan is a professor of economics at George Mason University and the author of several books, including Open Borders - The Science and Ethics of Immigration , The Case Against Education and the Myth of the Rational Voter . Niklas sits down with Bryan to talk about his new books and why markets often work b...
Ep. 100: A Conversation with Dr. Mary Ruwart: The Lost Innovation Cost of the FDA, and How Founders Can Reclaim the Right to Build 31.10.2025 1:17:21
Niklas sits down with biomedical researcher and libertarian author Mary Ruwart ( Death by Regulation ) to dissect how decades of FDA rules derailed innovation, extended timelines from 4 to 14 years, and quietly reshaped the entire pharma industry, from discovery to delivery. Together, they unpack: * The pivotal moments: 1962’s Kefeuver-Harris amendments and 1992’s PDUFA and how they changed the ga...
Ep. 99: A Conversation with Cremieux - How to Tell Good Science from Junk, and What’s Next in US Biotech & Deregulation 23.09.2025 1:07:52
Cremieux went from arguing against the death penalty as a teenager to becoming one of the most influential voices dissecting science online. Now with 250k+ followers on X, he’s known for exposing p-hacking, outcome switching, and selection effects that skew research. In this conversation with Niklas, here’s what they actually talk about: why effect sizes in journals rarely match FDA data, how gene...
Ep. 98: A Conversation with Adam Thierer: The War on Computation - Why AI Must Stay Permissionless 12.09.2025 55:48
Two years ago, policymakers floated a global AI pause, some even suggested bombing data centers to stop progress. Today, the U.S. is pulling back from the brink. Adam Thierer, author of Permissionless Innovation and Evasive Entrepreneurs , joins Niklas to unpack: * How the “war on computation” began and the moment the tide turned * Why sectors “born free” explode with innovation, while “born in ca...
Ep. 97: Dr. Michael Levin on Bioelectricity, Anthrobots, and the Software of Life 29.08.2025 1:01:18
In this episode, Michael Levin, Director of the Allen Discovery Center at Tufts , breaks down how his lab is rethinking regeneration, cancer, and aging, not through genetics, but through bioelectricity as the software of life . From pioneering living robots made from frog skin cells to repairing birth defects and regenerating limbs, Levin’s work shows how tissues act as intelligent agents and how...
Ep. 96: Digital Nomads’ Individual Sovereignty and Regulatory Hacking in International Insurance Markets - A Conversation with SafetyWing CEO Sondre Rasch 14.08.2025 1:03:39
In this episode, Sondre Rasch, founder & CEO of SafetyWing, breaks down how his team is building global health insurance and infrastructure for digital nomads, and what it takes to operate in one of the most regulated industries in the world. * From policy advisor in the Norwegian government to a $50M revenue insurance company * The legal and regulatory hacks that let SafetyWing serve nomads acros...
Podcasts similares
Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos